Financials • MiNK Therapeutics

INKT

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year	Revenue	EBITDA	Net Inc	Net Mrg	EPS	Equity	ROE	Net Debt Aj	ND/EBITDA Aj	OCF Aj	Capex	FCF	Free Aj	Buyback	Dividend	Payout	DY
12/2019	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2020	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345	$1,345
12/2021	0	-28	-12	0%	L	24	L	-39	-	-15	-0	49	-15	0	0	-	-
12/2022	0	-31	-12	0%	L	-0	L	-20	-	-22	-0	-0	-22	-0	0	-	-
12/2023	0	-23	-12	0%	L	-18	L	-3	-	-20	-0	-0	-20	-0	0	-	-
12/2024	0	-11	-12	0%	L	-20	L	0	L	-11	0	11	-11	0	0	-	-
12/2025	0	-12	-12	0%	L	-14	L	-8	-	-9	0	15	-9	-0	0	-	-

To see all financials—including updated, you must be Premium.